The India pharmaceuticals market is witnessing rapid expansion due to rising healthcare expenditure, increasing chronic disease prevalence, strong generic drug manufacturing capabilities, and growing investments in biosimilars and specialty medicines. India continues to strengthen its position as the “pharmacy of the world,” supported by government initiatives, export growth, and technological advancements in drug manufacturing. The market was valued at USD 66.02 billion in 2024 and is projected to grow from USD 72.24 billion in 2025 to USD 145.09 billion by 2032, exhibiting a CAGR of 10.48% during the forecast period.

What is Driving the Growth of the India Pharmaceuticals Market?

India has emerged as one of the world’s largest pharmaceutical manufacturing hubs, especially in generic medicines, vaccines, and active pharmaceutical ingredients (APIs). The increasing burden of chronic diseases such as cancer, diabetes, cardiovascular disorders, and respiratory illnesses is accelerating the demand for advanced therapeutics and affordable medicines.

Government initiatives such as Production Linked Incentive (PLI) schemes, support for bulk drug parks, and rising public healthcare investments are also fueling industry growth. In addition, the growing penetration of online pharmacies, retail pharmacy chains, and healthcare digitization is improving medicine accessibility across urban and rural regions.

Rising Demand for Biosimilars and Specialty Drugs

One of the major trends shaping the India pharmaceuticals market is the increasing adoption of biologics and biosimilars. These products provide cost-effective alternatives to expensive biologic therapies and are gaining traction across oncology, autoimmune diseases, and chronic illness treatment.

Several pharmaceutical companies are investing heavily in research and development to launch innovative biosimilars. Collaborations between Indian and international pharma companies are further accelerating product commercialization and global market penetration.

Generic Drug Manufacturing Strengthening India’s Global Position

India is globally recognized for its leadership in generic medicine manufacturing. The country exports pharmaceutical products to more than 200 countries and maintains a significant share in global vaccine and generic drug supply.

High production capabilities, cost-effective manufacturing infrastructure, and a strong network of FDA-approved facilities continue to strengthen India’s pharmaceutical export ecosystem. Pharmaceutical exports from India reached USD 30.4 billion during FY25, highlighting the country’s expanding global footprint.

Download Free Sample: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/india-pharmaceuticals-market-113982

Segment Analysis

Drugs Segment Dominates the Market

Based on type, the drugs segment accounted for the largest market share in 2024 due to increasing demand for prescription medicines, chronic disease therapies, and generic formulations. The vaccines segment is also witnessing strong growth owing to immunization programs and rising global vaccine demand.

Oncology Segment Shows Significant Growth Potential

Among disease indications, oncology is projected to witness one of the highest growth rates during the forecast period. Rising cancer prevalence and increasing launch of affordable cancer therapeutics are contributing to segment growth. The diabetes segment also holds a significant share due to India’s growing diabetic population.

Oral Route of Administration Leads

The oral segment dominates the market owing to convenience, patient compliance, lower costs, and easy administration. Oral medications remain the preferred treatment option for multiple chronic diseases across India.

Retail Pharmacies Continue to Lead Distribution

Retail pharmacies account for a major share of pharmaceutical distribution in India due to their widespread network and accessibility. Meanwhile, online pharmacies are rapidly expanding because of increasing digital adoption and home delivery services.

Competitive Landscape

The India pharmaceuticals market is highly competitive, with both domestic and international players focusing on product innovation, acquisitions, collaborations, and expansion strategies. Key companies are increasing investments in specialty medicines, biosimilars, and research-driven therapeutics to strengthen their market presence.

Major companies operating in the market include:

• Sun Pharmaceutical Industries
• Pfizer Inc.
• Johnson & Johnson
• AbbVie Inc.
• AstraZeneca
• Novartis AG
• Sanofi
• Novo Nordisk A/S
• GSK plc
• Takeda Pharmaceutical Company Limited

Source: https://www.fortunebusinessinsights.com/india-pharmaceuticals-market-113982

Regional Outlook

India’s pharmaceutical industry is expanding rapidly across major metropolitan regions including Maharashtra, Gujarat, Telangana, Karnataka, and Andhra Pradesh due to strong manufacturing infrastructure and biotechnology investments. Northern and Southern India continue to emerge as major pharmaceutical production and research hubs.

Future Outlook

The future of the India pharmaceuticals market looks highly promising due to increasing healthcare awareness, expanding pharmaceutical exports, rising biologics adoption, and favorable government policies. The integration of digital healthcare technologies, AI-driven drug discovery, and advanced manufacturing capabilities is expected to further transform the pharmaceutical ecosystem in India.

Growing demand for affordable healthcare solutions, coupled with rising investments in R&D and biosimilars, will continue to create substantial growth opportunities for pharmaceutical manufacturers over the coming years.